Edgewise Therapeutics, Inc. (EWTX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-98.7%

$0.50

vs $38.11 price

Levered DCF

$0.56

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

75.67

Safe zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-15.23×	-18.41×	-6.97×	-7.1×	-17.77×	-85.71×	-157.89×
P/B	4.89×	5.37×	2.19×	1.38×	2.76×	-44.18×	-87.61×
P/S	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-15.09×	-18.48×	-6.26×	-7.32×	-17.41×	-90.07×	-148.24×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	19.85×	19.93×	19.5×	21.53×	26.97×	29.86×	21.24×
Debt / equity	0.01×	0.01×	0.02×	0.01×	0×	-4.79×	0×
Interest coverage	0×	0×	0×	-17.83×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-32.1%	-29.1%	-31.4%	-19.5%	-15.6%	51.0%	56.3%
Return on invested capital	-36.4%	-34.2%	-35.3%	-20.4%	-15.7%	-13.6%	-42.4%
Return on assets	-30.4%	-27.5%	-29.5%	-18.4%	-15.0%	-13.0%	-38.7%
Free cash flow yield	-5.6%	-4.5%	-14.0%	-12.1%	-4.5%	-1.0%	-0.6%
Earnings yield	-6.6%	-5.4%	-14.4%	-14.1%	-5.7%	-1.2%	-0.6%
Enterprise value	$2.5B	$2.4B	$616.5M	$461.5M	$740.8M	$1.5B	$1.5B
Net debt / EBITDA	0.35×	0.28×	0.82×	0.28×	0.37×	-3.25×	2.41×
Cash conversion cycle (days)	-967	0	0	0	0	-3,117	-1,979